Secukinumab is a fully human anti-IL-17A monoclonal antibody approved for the treatment of PsA, psoriasis, and ankylosing spondylitis following the favorable results of several large RCTs [86,87,88,89,90,91]. Here, IL17A is linked to psoriasis.